Prostate MRI solution OnQ Prostate launches on US market

Cortechs.ai has announced the commercial launch of their novel prostate MRI solution, OnQ Prostate, which is an FDA-cleared post-processing software that can aid radiologists in the detection of clinically significant prostate cancer, the company announced in a news release.¹

One study showed that RSI with mpMRI improved prostate cancer detection vs mpMRI alone (85% accuracy vs 79% accuracy; P = 0.04).

This launch marks the company’s expansion into the urologic oncology market. For years, Cortechs.ai has had a focus on neuroradiology with their product NeuroQuant.

Their new product, OnQ Prostate, goes beyond traditional diffusion-weighted imaging by using a method called Restriction Spectrum Imaging (RSI), which allows for better detection of restricted diffusion that may be indicative of prostate cancer.

According to the news release, “Studies on RSI in the prostate have shown improved MR-based cancer detection and correlation with underlying histopathology compared to conventional imaging.”^1,2

Prior to the launch of the solution, OnQ Prostate was limited to a select number of academic institutions and imaging centers to validate the tool and gather feedback.

"This announcement is an important step in increasing the awareness and accessibility of OnQ Prostate beyond its earliest adopters, so that more physicians and patients can benefit from this technology," said Brittany Hunt, Head of Prostate Business Development at Cortechs.ai, in the news release.¹

The company also noted in the news release that, using RSI technology, OnQ Prostate can offer improved PI-RADS accuracy, inter-reader agreement, and workflow efficiency vs conventional imaging. One study showed that RSI with mpMRI improved prostate cancer detection vs mpMRI alone (85% accuracy vs 79% accuracy; P = 0.04), andRSI plus T2-weightedimaging achieved similar prostate cancer detection as MP-MRI alone (80% accuracy vs 79% accuracy).³

Further, the solution may enable non-radiologists to more easily interpret and interact with scans, which can be helpful for urologists in patient-selection for biopsy and treatment.

Kyle Frye, CEO of Cortechs.ai, concluded in the news release,¹ "We are consistently striving to be at the forefront of innovation and bringing best in class value to our users and patients. Our OnQ Prostate product continues to showcase this focus. We are going beyond the brain and utilizing our RSI technology to those focused on diagnosing and treating patients with prostate cancer. Patients and users deserve to have a more specific and efficient technology that will allow for diagnosis and subsequent treatments to happen. We couldn't be more excited to launch our technology into the market."

References

1. Cortechs.ai launches into the urologic oncology market with novel prostate imaging solution. News release. Cortechs.ai. May 28, 2024. Accessed May 29, 2024. https://www.prnewswire.com/news-releases/cortechsai-launches-into-the-urologic-oncology-market-with-novel-prostate-imaging-solution-302154948.html?tc=eml_cleartime

2. McCammack KC, Kane CJ, Parsons JK, et al. In vivo prostate cancer detection and grading using restriction spectrum imaging-MRI. Prostate Cancer Prostatic Dis. 2016;19(2):168-73. doi:10.1038/pcan.2015.61

3. McCammack KC, Schenker-Ahmed NM, White NS, et al. Restriction spectrum imaging improves MRI-based prostate cancer detection. Abdom Radiol (NY). 2016;41(5):946-53. doi:10.1007/s00261-016-0659-1